• Users Online: 35
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2011  |  Volume : 2  |  Issue : 4  |  Page : 291-293

Four Decades of Chelation Therapy for β-Thalassemia Major

Ain Shams University, ESPHO President & ICIS Board Member, Cairo, Egypt

Date of Web Publication30-Jun-2014

Correspondence Address:
Mohsen Saleh Elalfy
Ain Shams University, ESPHO President & ICIS Board Member, Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

After discussing the need for iron-chelating therapy with b-thalassemia major patients and their families, we describe the advantages and disadvantages of available chelators-subcutaneous desferrioxamine (DFO), oral deferiprone (DFP), and deferasirox (DFX)-so that a genuinely informed decision can be made. At present, the most frequent choices are either oral DFP or DFX. patient information about the number of previous transfusions and the rate of ongoing transfusion and arrange for hepatic transverse relaxation rate measurements, magnetic resonance imaging evaluation of cardiac T2*, and echocardiographic and electrocardiographic studies. Auditory and ophthalmic testing, including slit-lamp and fundus examinations, are also performed. Laboratory tests include a complete blood count with a differential count and measurement of serum creatinine, protein/creatinine ratio, serum aminotransferases, bilirubin levels, and iron indexes. After transfusing 10-12 units of blood, or reaching a hepatic iron concentration between 3 and 7 mg/g, we prescribe either once-daily oral DFX therapy (20 mg/kg) or DFP (75 mg/kg/d) in escalating doses. Monitoring efficacy and adverse events is valuable. Ideally, iron-chelating therapy should be initiated on a prophylactic basis before clinically significant iron accumulation has occurred. Patients who have already undergone repeated transfusion without sufficient chelation can also be treated successfully.

How to cite this article:
Elalfy MS. Four Decades of Chelation Therapy for β-Thalassemia Major. J Appl Hematol 2011;2:291-3

How to cite this URL:
Elalfy MS. Four Decades of Chelation Therapy for β-Thalassemia Major. J Appl Hematol [serial online] 2011 [cited 2020 Jun 4];2:291-3. Available from: http://www.jahjournal.org/text.asp?2011/2/4/291/135584



Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal